Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Literature
1.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRef
2.
Yamazaki H, Suzuki M, Otsuki A et al (2014) A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25:415–427CrossRef
3.
Pintado T, Ferro MT, San Roman C et al (1985) Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 55:535–541CrossRef
4.
Reiter E, Greinix H, Rabitsch W, Keil F, Schwarzinger I, Jaeger U, Lechner K, Worel N, Streubel B, Fonatsch C, Mitterbauer G, Kalhs P (2000) Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversion inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol 79:374–377CrossRef
5.
Villalon C, Talavera M, Sordo MT et al (2008) Association of inv(3)(q21q26) with essential thrombocythemia in transformation. Cancer Genet Cytogenet 184:122–123CrossRef
Metadata
Title
Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26)
Authors
Radhika Gangaraju
Andrew J. Carroll
Josef T. Prchal
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 12/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03805-9

Other articles of this Issue 12/2019

Annals of Hematology 12/2019 Go to the issue

Letter to the Editor

Hemoglobin Kirklareli [Α2 59(E7) His>Leu; HBA2:c.176A>T] in a Brazilian child with severe dyspnea and low O2 saturation

Original Article

Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia

Original Article

Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group

Letter to the Editor

Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia

Letter to the Editor

A new SH2D1A mutation in a female adult XLP disease with hemophagocytic lymphohistiocytosis and NK-cell leukemia

Original Article

Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits